These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7544736)

  • 1. Late effects of intravesical bacillus Calmette-Guérin immunotherapy on bladder mucosa infiltrating lymphocytes: an immunohistochemical study.
    Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Betta PG
    Eur Urol; 1995; 27(4):334-8. PubMed ID: 7544736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma.
    Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Annoscia S; Lozzi C; Betta PG
    Eur Urol; 1992; 21(4):304-8. PubMed ID: 1459153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment.
    Saint F; Patard JJ; Groux Muscatelli B; Lefrere Belda MA; Gil Diez de Medina S; Abbou CC; Chopin DK
    BJU Int; 2001 Oct; 88(6):602-10. PubMed ID: 11678759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytological, histological, and clinical correlations in intravesical Bacillus Calmette-Guerin immunotherapy.
    Bhan R; Pisharodi LR; Gudlaugsson E; Bedrossian C
    Ann Diagn Pathol; 1998 Feb; 2(1):55-60. PubMed ID: 9845722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical study of tumor-infiltrating lymphocytes before and after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer.
    Honda S; Sakamoto Y; Fujime M; Kitagawa R
    Int J Urol; 1997 Jan; 4(1):68-73. PubMed ID: 9179670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
    Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
    J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
    Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
    Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences.
    Böhle A; Busemann E; Gerdes J; Ulmer AJ; Flad HD; Jocham D
    Dev Biol Stand; 1992; 77():199-209. PubMed ID: 1426663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.
    Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD
    J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
    Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.
    Kavoussi LR; Brown EJ; Ritchey JK; Ratliff TL
    J Clin Invest; 1990 Jan; 85(1):62-7. PubMed ID: 2404029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer.
    Zlotta AR; Drowart A; Huygen K; De Bruyn J; Shekarsarai H; Decock M; Pirson M; Jurion F; Palfliet K; Denis O; Mascart F; Simon J; Schulman CC; Van Vooren JP
    Clin Exp Immunol; 1997 Jul; 109(1):157-65. PubMed ID: 9218839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
    Ratliff TL; Palmer JO; McGarr JA; Brown EJ
    Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future directions in bladder cancer immunotherapy: towards adaptive immunity.
    Smith SG; Zaharoff DA
    Immunotherapy; 2016; 8(3):351-65. PubMed ID: 26860539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.